The global proteasome inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Proteasomes are protein complexes that degrade unneeded or damaged proteins by proteolysis. Additionally, enzymes that support such reactions are known as proteases. Furthermore, the proteasome is a cylindrical complex that contains a core of four stacked rings which forms a central pore. The major factor driving the growth of the market is the rising prevalence of lymphoma across the globe. 

According to the Leukemia & Lymphoma Society, one person is diagnosed with lymphoma approximately every 3 minutes in the US. Additionally, in 2021, an estimated combined total of 186,400 people are anticipated to be diagnosed with leukemia, lymphoma or myeloma in the US. Furthermore, in 2021, new cases of leukemia, lymphoma and myeloma are anticipated to account for 9.8% of the estimated 1,898,160 new cancer cases. Moreover, an estimated 1,519,907 people are living with or in remission from leukemia, lymphoma, myeloma in the US. Hence, the increasing prevalence of lymphoma is driving the demand for proteasome inhibitors as they mediate cell cycle arrest and apoptosis causing dysregulation of several proapoptotic proteins.

Some major players in the market include Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Oncopeptides AB announced that it has received approval for melphalan flufenamide from the US FDA. It is used in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drugs

o By Application

o By Distribution Channel

o By End-Users

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Proteasome Inhibitors Market Report by Segment

By Drugs 

• Bortezomib

• Carfilzomib

• Ixazomib

By Application

• Lymphoma

• Mantle Cell Lymphoma

• Multiple Myeloma

By Distribution Channel 

• Hospital Pharmacy

• Online Pharmacy

• Retail Pharmacy

Global Proteasome Inhibitors Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa